Advertisement

Anti-inflammatory Agents for the Treatment of Depression in the Light of Comorbid Cardiovascular Disease

  • Ole Köhler
  • Christiane Gasse
Chapter

Abstract

A growing body of evidence supports the role of inflammation as a common etiological factor of the pathophysiology of depression and cardiovascular diseases. Recent clinical studies have indicated that different anti-inflammatory agents may yield antidepressant treatment effects, both as add-on and monotherapy. However, cardiac side effects emphasize cautious use of several agents, whereas other agents might have beneficial effects on both depression and cardiovascular disease. The current chapter aims to review the most promising anti-inflammatory agents that have been studied in depressed individuals and other patient groups including their potential underlying mechanisms. The most frequently investigated agents are nonsteroidal anti-inflammatory drugs (NSAIDs), monoclonal antibodies, and polyunsaturated fatty acids, but antidepressant properties were also observed for statins, minocycline, pioglitazone, cortisol, modafinil, and angiotensin-2 receptor antagonists. In addition, this chapter will discuss important clinical aspects for identifying patient groups which will be most likely to benefit of anti-inflammatory treatment, such as biological markers potentially predicting antidepressant treatment effects of anti-inflammatory intervention, timing and duration of anti-inflammatory intervention, and targeting specific depressive symptoms. Finally, we will discuss which anti-inflammatory agents, e.g., statins and low-dose acetylsalicylic acid, may represent relevant add-on treatment strategies in patients suffering of comorbid depression and cardiovascular diseases.

Keywords

Depression Cardiovascular disease Inflammation Anti-inflammatory agents Personalized treatment 

References

  1. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S (2012) Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 141:308–314CrossRefPubMedGoogle Scholar
  2. Abolfazli R, Hosseini M, Ghanizadeh A, Ghaleiha A, Tabrizi M, Raznahan M, Golalizadeh M, Akhondzadeh S (2011) Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depress Anxiety 28:297–302CrossRefPubMedGoogle Scholar
  3. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A (2009) Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26:607–611CrossRefPubMedGoogle Scholar
  4. Anderson G, Berk M, Dean O, Moylan S, Maes M (2013) Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications. CNS Drugs 28:1–10Google Scholar
  5. Andrade C, Kumar CB, Surya S (2013) Cardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failure. Int Clin Psychopharmacol 28:145–155CrossRefPubMedGoogle Scholar
  6. Arana GW, Santos AB, Laraia MT, McLeod-Bryant S, Beale MD, Rames LJ, Roberts JM, Dias JK, Molloy M (1995) Dexamethasone for the treatment of depression: a randomized, placebo- controlled, double-blind trial. Am J Psychiatry 152:265–267CrossRefPubMedGoogle Scholar
  7. Baune BT (2015) Inflammation and neurodegenerative disorders: is there still hope for therapeutic intervention? Curr Opin Psychiatry 28:148–154PubMedGoogle Scholar
  8. Bechter K, Reiber H, Herzog S, Fuchs D, Tumani H, Maxeiner HG (2010) Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res 44:321–330CrossRefPubMedGoogle Scholar
  9. Berk M, Dean O, Drexhage H, McNeil JJ, Moylan S, O’Neil A, Davey CG, Sanna L, Maes M (2013) Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med 11:74, 7015-11-74CrossRefPubMedPubMedCentralGoogle Scholar
  10. Bloch MH, Hannestad J (2012) Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry 17:1272–1282CrossRefPubMedGoogle Scholar
  11. Burke NN, Kerr DM, Moriarty O, Finn DP, Roche M (2014) Minocycline modulates neuropathic pain behaviour and cortical M1-M2 microglial gene expression in a rat model of depression. Brain Behav Immun 42:147–156CrossRefPubMedGoogle Scholar
  12. Casolini P, Catalani A, Zuena AR, Angelucci L (2002) Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 68:337–343CrossRefPubMedGoogle Scholar
  13. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS, Scientific Advisory B, the Executive Committee of the Grand Challenges on Global Mental Health, Anderson W, Dhansay MA, Phillips A, Shurin S, Walport M, Ewart W, Savill SJ, Bordin IA, Costello EJ, Durkin M, Fairburn C, Glass RI, Hall W, Huang Y, Hyman SE, Jamison K, Kaaya S, Kapur S, Kleinman A, Ogunniyi A, Otero-Ojeda A, Poo MM, Ravindranath V, Sahakian BJ, Saxena S, Singer PA, Stein DJ (2011) Grand challenges in global mental health. Nature 475:27–30CrossRefPubMedPubMedCentralGoogle Scholar
  14. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56CrossRefPubMedPubMedCentralGoogle Scholar
  15. de Abajo FJ, Garcia-Rodriguez LA (2008) Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 65:795–803CrossRefPubMedGoogle Scholar
  16. De Berardis D, Marini S, Piersanti M, Cavuto M, Perna G, Valchera A, Mazza M, Fornaro M, Iasevoli F, Martinotti G, Di Giannantonio M (2012) The relationships between cholesterol and suicide: an update. ISRN Psychiatry 2012:387901CrossRefPubMedPubMedCentralGoogle Scholar
  17. de Gois Queiroz AI, Medeiros CD, Ribeiro BM, de Lucena DF, Macedo DS (2013) Angiotensin receptor blockers for bipolar disorder. Med Hypotheses 80:259–263CrossRefPubMedGoogle Scholar
  18. Dean OM, Maes M, Ashton M, Berk L, Kanchanatawan B, Sughondhabirom A, Tangwongchai S, Ng C, Dowling N, Malhi GS, Berk M (2014) Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial. Clin Psychopharmacol Neurosci 12:180–188CrossRefPubMedPubMedCentralGoogle Scholar
  19. DeBattista C, Posener JA, Kalehzan BM, Schatzberg AF (2000) Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. Am J Psychiatry 157:1334–1337CrossRefPubMedGoogle Scholar
  20. Eyre HA, Stuart MJ, Baune BT (2014) A phase-specific neuroimmune model of clinical depression. Prog Neuropsychopharmacol Biol Psychiatry 54:265–274CrossRefPubMedGoogle Scholar
  21. Eyre HA, Air T, Proctor S, Rositano S, Baune BT (2015) A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. Prog Neuropsychopharmacol Biol Psychiatry 57:11–16CrossRefPubMedGoogle Scholar
  22. Fields C, Drye L, Vaidya V, Lyketsos C (2012) Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am J Geriatr Psychiatry 20:505–513CrossRefPubMedPubMedCentralGoogle Scholar
  23. Fond G, Hamdani N, Kapczinski F, Boukouaci W, Drancourt N, Dargel A, Oliveira J, Le Guen E, Marlinge E, Tamouza R, Leboyer M (2013) Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand 129:163–179Google Scholar
  24. Foody J (2010) Statin use associated with increased risk of cataract, myopathy, liver dysfunction and acute renal failure with varying numbers needed to harm. Evid-Based Med 15:187–188CrossRefPubMedGoogle Scholar
  25. Gallagher PJ, Castro V, Fava M, Weilburg JB, Murphy SN, Gainer VS, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH (2012) Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry 169:1065–1072CrossRefPubMedPubMedCentralGoogle Scholar
  26. Garrido-Mesa N, Zarzuelo A, Galvez J (2013) What is behind the non-antibiotic properties of minocycline? Pharmacol Res 67:18–30CrossRefPubMedGoogle Scholar
  27. Ghanizadeh A, Hedayati A (2013) Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial. Depress Anxiety 30:1084–1088CrossRefPubMedGoogle Scholar
  28. Gharekhani A, Khatami MR, Dashti-Khavidaki S, Razeghi E, Noorbala AA, Hashemi-Nazari SS, Mansournia MA (2014) The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial. Eur J Clin Pharmacol 70:655–665CrossRefPubMedGoogle Scholar
  29. Glaus J, Vandeleur CL, Lasserre AM, Strippoli MP, Castelao E, Gholam-Rezaee M, Waeber G, Aubry JM, Vollenweider P, Preisig M (2015) Aspirin and statin use and the subsequent development of depression in men and women: results from a longitudinal population-based study. J Affect Disord 182:126–131CrossRefPubMedGoogle Scholar
  30. Goldstein MR, Mascitelli L (2009) Do statins decrease cardiovascular disease at the expense of increasing cancer? Int J Cardiol 133:254–255CrossRefPubMedGoogle Scholar
  31. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH (2013) Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 74:1101–1107CrossRefPubMedGoogle Scholar
  32. Gougol A, Zareh-Mohammadi N, Raheb S, Farokhnia M, Salimi S, Iranpour N, Yekehtaz H, Akhondzadeh S (2015) Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: a double-blind placebo-controlled trial. J Psychopharmacol 29:575–581CrossRefPubMedGoogle Scholar
  33. Hashemian F, Majd M, Hosseini SM, Sharifi A, Panahi MVS, Bigdeli O (2011) A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in the treatment of a drug-naive women with major depression. Klin Psikofarmakol Bull 21:S183–S184Google Scholar
  34. Hippisley-Cox J, Coupland C (2010) Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340:c2197CrossRefPubMedPubMedCentralGoogle Scholar
  35. Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom Med 71:171–186CrossRefPubMedGoogle Scholar
  36. Iyengar RL, Gandhi S, Aneja A, Thorpe K, Razzouk L, Greenberg J, Mosovich S, Farkouh ME (2013) NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am J Med 126:1017.e11–8CrossRefGoogle Scholar
  37. Jung JC, Lee Y, Son JY, Lim E, Jung M, Oh S (2012) Simple synthesis of modafinil derivatives and their anti-inflammatory activity. Molecules 17:10446–10458CrossRefPubMedGoogle Scholar
  38. Kalra J, Prakash A, Kumar P, Majeed AB (2015) Cerebroprotective effects of RAS inhibitors: beyond their cardio-renal actions. J Renin Angiotensin Aldosterone Syst 16:459–468CrossRefPubMedGoogle Scholar
  39. Kashani L, Omidvar T, Farazmand B, Modabbernia A, Ramzanzadeh F, Tehraninejad ES, Ashrafi M, Tabrizi M, Akhondzadeh S (2013) Does pioglitazone improve depression through insulin-sensitization? results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology 38:767–776CrossRefPubMedGoogle Scholar
  40. Knights KM, Mangoni AA, Miners JO (2010) Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol 3:769–776CrossRefPubMedGoogle Scholar
  41. Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, Krogh J (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71:1381–1391Google Scholar
  42. Köhler O, Petersen L, Mors O, Gasse C (2015) Inflammation and depression: combined use of selective serotonin-reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes. Brain Behav 5:e00338Google Scholar
  43. Köhler O, Gasse C, Petersen L, Nierenberg A, Mors O, Østergaard S (2016) The effect of concomitant treatment with selective serotonin reuptake inhibitors and statins: a population-based study. Am J Psychiatry May 3:appiajp201615040463Google Scholar
  44. Krishnadas R, Cavanagh J (2012) Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry 83:495–502CrossRefPubMedGoogle Scholar
  45. Krogh J, Benros ME, Jorgensen MB, Vesterager L, Elfving B, Nordentoft M (2014) The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav Immun 35:70–76CrossRefPubMedGoogle Scholar
  46. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu M, Ortonne J, Gordon KB, Kimball AB (2010) Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 63:457–465CrossRefPubMedGoogle Scholar
  47. Maes M (1995) Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19:11–38CrossRefPubMedGoogle Scholar
  48. Mansi I, Frei CR, Pugh MJ, Mortensen EM (2013) Psychologic disorders and statin use: a propensity score-matched analysis. Pharmacotherapy 33:615–626CrossRefPubMedPubMedCentralGoogle Scholar
  49. Martino M, Rocchi G, Escelsior A, Fornaro M (2012) Immunomodulation mechanism of antidepressants: interactions between Serotonin/Norepinephrine balance and Th1/Th2 balance. Curr Neuropharmacol 10:97–123CrossRefPubMedPubMedCentralGoogle Scholar
  50. Martins JG, Bentsen H, Puri BK (2012) Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and hannestad and updated meta-analysis. Mol Psychiatry 17:1144–1149; discussion 1163–7CrossRefPubMedGoogle Scholar
  51. Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N (2006) Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 21:227–231CrossRefPubMedGoogle Scholar
  52. Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P (2010) The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 62:812–818CrossRefPubMedGoogle Scholar
  53. Mischoulon D, Nierenberg AA, Schettler PJ, Kinkead BL, Fehling K, Martinson MA, Hyman Rapaport M (2015) A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J Clin Psychiatry 76:54–61Google Scholar
  54. Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, Tsuchie K, Taki M, Ishihara K, Araki T, Horiguchi J (2012) Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuro-Psychopharmacol Biol Psychiatry 37:222–226CrossRefGoogle Scholar
  55. Muller N, Riedel M, Schwarz MJ, Engel RR (2005) Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 255:149–151CrossRefPubMedGoogle Scholar
  56. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Moller HJ, Arolt V, Riedel M (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11:680–684CrossRefPubMedGoogle Scholar
  57. Muller N, Myint AM, Schwarz MJ (2011) Inflammatory biomarkers and depression. Neurotox Res 19:308–318CrossRefPubMedGoogle Scholar
  58. Musil R, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I, Arolt V, Muller N (2011) Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment. J Affect Disord 134:217–225CrossRefPubMedGoogle Scholar
  59. O’Leary OF, Dinan TG, Cryan JF (2015) Faster, better, stronger: towards new antidepressant therapeutic strategies. Eur J Pharmacol 753:32–50CrossRefPubMedGoogle Scholar
  60. Oh SW, Kim J, Myung SK, Hwang SS, Yoon DH (2014) Antidepressant use and risk of coronary heart disease: meta-analysis of observational studies. Br J Clin Pharmacol 78:727–737CrossRefPubMedPubMedCentralGoogle Scholar
  61. Otte C, Zhao S, Whooley MA (2012) Statin use and risk of depression in patients with coronary heart disease: longitudinal data from the heart and soul study. J Clin Psychiatry 73:610–615CrossRefPubMedGoogle Scholar
  62. Parsaik AK, Singh B, Hassan Murad M, Singh K, Mascarenhas SS, Williams MD, Lapid MI, Richardson JW, West CP, Rummans TA (2014) Statins use and risk of depression: a systematic review and meta-analysis. J Affect Disord 160:62–67CrossRefPubMedGoogle Scholar
  63. Ping G, Qian W, Song G, Zhaochun S (2014) Valsartan reverses depressive/anxiety-like behavior and induces hippocampal neurogenesis and expression of BDNF protein in unpredictable chronic mild stress mice. Pharmacol Biochem Behav 124:5–12CrossRefPubMedGoogle Scholar
  64. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70:31–41CrossRefPubMedPubMedCentralGoogle Scholar
  65. Redlich C, Berk M, Williams LJ, Sundquist J, Sundquist K, Li X (2014) Statin use and risk of depression: a Swedish national cohort study. JAMA Psychiatry 14:348, 014-0348-yGoogle Scholar
  66. Regen F, Le Bret N, Hildebrand M, Herzog I, Heuser I, Hellmann-Regen J (2015) Inhibition of brain retinoic acid catabolism: a mechanism for minocycline’s pleiotropic actions? World J Biol Psychiatry June 5:1–7Google Scholar
  67. Reiner Z (2013) Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 10:453–464CrossRefPubMedGoogle Scholar
  68. Rosenblat JD, Cha DS, Mansur RB, McIntyre RS (2014) Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 53C:23–34CrossRefGoogle Scholar
  69. Sahin TD, Karson A, Balci F, Yazir Y, Bayramgurler D, Utkan T (2015) TNF-alpha inhibition prevents cognitive decline and maintains hippocampal BDNF levels in the unpredictable chronic mild stress rat model of depression. Behav Brain Res 292:233–240CrossRefPubMedGoogle Scholar
  70. Sampey AV, Hall PH, Mitchell RA, Metz CN, Morand EF (2001) Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. Arthritis Rheum 44:1273–1280CrossRefPubMedGoogle Scholar
  71. Sandrini M, Vitale G, Pini LA (2002) Effect of rofecoxib on nociception and the serotonin system in the rat brain. Inflamm Res 51:154–159CrossRefPubMedGoogle Scholar
  72. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Kober L, Hansen PR, Torp-Pedersen C, Gislason GH (2011) Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 123:2226–2235CrossRefPubMedGoogle Scholar
  73. Schjerning Olsen AM, Fosbol EL, Gislason GH (2014) The impact of NSAID treatment on cardiovascular risk - insight from danish observational data. Basic Clin Pharmacol Toxicol 115:179–184CrossRefPubMedGoogle Scholar
  74. Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia M, Akhondzadeh S (2012) Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology 37:2093–2100CrossRefPubMedPubMedCentralGoogle Scholar
  75. Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, Suridjan I, Kennedy JL, Rekkas PV, Houle S, Meyer JH (2015) Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 72:268–275CrossRefPubMedPubMedCentralGoogle Scholar
  76. Soczynska JK, Mansur RB, Brietzke E, Swardfager W, Kennedy SH, Woldeyohannes HO, Powell AM, Manierka MS, McIntyre RS (2012) Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res 235:302–317CrossRefPubMedGoogle Scholar
  77. Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S (2006) Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 54:1378–1389CrossRefPubMedGoogle Scholar
  78. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E (2008) Cross trial safety assessment group: cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117:2104–2113CrossRefPubMedPubMedCentralGoogle Scholar
  79. Sumowski JF, Leavitt VM (2014) Body temperature is elevated and linked to fatigue in relapsing-remitting multiple sclerosis, even without heat exposure. Arch Phys Med Rehabil 95:1298–1302CrossRefPubMedPubMedCentralGoogle Scholar
  80. Tomas-Camardiel M, Rite I, Herrera AJ, de Pablos RM, Cano J, Machado A, Venero JL (2004) Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis 16:190–201CrossRefPubMedGoogle Scholar
  81. Toussi SS, Pan N, Walters HM, Walsh TJ (2013) Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-alpha inhibitors: systematic review of the literature. Clin Infect Dis 57:1318–1330CrossRefPubMedPubMedCentralGoogle Scholar
  82. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367:29–35CrossRefPubMedGoogle Scholar
  83. Uher R, Carver S, Power RA, Mors O, Maier W, Rietschel M, Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Placentino A, Farmer A, McGuffin P (2012) Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychol Med 42:2027–2035CrossRefPubMedGoogle Scholar
  84. Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Farmer A, McGuffin P (2014) An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry 171:1278–1286CrossRefPubMedGoogle Scholar
  85. Vevera J, Fisar Z, Kvasnicka T, Zdenek H, Starkova L, Ceska R, Papezova H (2005) Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res 133:197–203CrossRefPubMedGoogle Scholar
  86. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P (2011) Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 108:9262–9267CrossRefPubMedPubMedCentralGoogle Scholar
  87. Weitz-Schmidt G (2002) Statins as anti-inflammatory agents. Trends Pharmacol Sci 23:482–486CrossRefPubMedGoogle Scholar
  88. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687–692CrossRefPubMedGoogle Scholar
  89. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M (2005) IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 10:538–544CrossRefPubMedGoogle Scholar
  90. Wingerchuk DM, Benarroch EE, O’Brien PC, Keegan BM, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M (2005) A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 64:1267–1269CrossRefPubMedGoogle Scholar
  91. Yekehtaz H, Farokhnia M, Akhondzadeh S (2013) Cardiovascular considerations in antidepressant therapy: an evidence-based review. J Tehran Heart Cent 8:169–176PubMedPubMedCentralGoogle Scholar
  92. You H, Lu W, Zhao S, Hu Z, Zhang J (2013) The relationship between statins and depression: a review of the literature. Expert Opin Pharmacother 14:1467–1476CrossRefPubMedGoogle Scholar
  93. Young-Xu Y, Chan KA, Liao JK, Ravid S, Blatt CM (2003) Long-term statin use and psychological well-being. J Am Coll Cardiol 42:690–697CrossRefPubMedPubMedCentralGoogle Scholar
  94. Zernecke A, Bernhagen J, Weber C (2008) Macrophage migration inhibitory factor in cardiovascular disease. Circulation 117:1594–1602CrossRefPubMedGoogle Scholar
  95. Zuidersma M, Conradi HJ, van Melle JP, Ormel J, de Jonge P (2013) Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. J Psychosom Res 74:25–30CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Psychosis Research UnitAarhus University HospitalRisskovDenmark
  2. 2.National Center for Register-based Research (NCRR), Department of Economics and Business EconomicsAarhus BSS, Aarhus UniversityAarhusDenmark

Personalised recommendations